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PIWI-interacting RNAs (piRNAs) are a large family of small, single-stranded, non-coding RNAs present throughout
the animal kingdom. They form complexes with several members of the PIWI clade of Argonaute proteins and carry
out regulatory functions. Their best established biological role is the inhibition of transposon mobilization, which
they enforce both at the transcriptional level, through regulation of heterochromatin formation, and by promoting
transcript degradation. In this capacity, piRNAs and PIWI proteins are at the heart of the germline cells’ efforts to
preserve genome integrity. Additional regulatory roles of piRNAs and PIWI proteins in gene expression are
becoming increasingly apparent.
PIWI proteins and piRNAs are often detected in human cancers deriving from germline cells as well as somatic
tissues. Their detection in cancer correlates with poorer clinical outcomes, suggesting that they play a functional
role in the biology of cancer. Nonetheless, the currently available information, while highly suggestive, is still not
sufficient to entirely discriminate between a ‘passenger’ role for the ectopic expression of piRNAs and PIWI proteins
in cancer from a ‘driver’ role in the pathogenesis of these diseases. In this article, we review some of the key
available evidence for the role of piRNAs and PIWI in human cancer and discuss ways in which our understanding
of their functions may be improved.Transposon mobilization and genome instability
in cancer
As most cancers stem from the accumulation of muta-
tions, genome instability, defined as a propensity to have
mutations, is an ‘enabling characteristic’ of tumor cells
[1,2]. There are multiple sources of genome instability in
cancer, ranging from exposure to environmental geno-
toxic substances, to endogenous generation of reactive
species of a metabolic origin, resulting in DNA damage.
In addition, the human genome carries a plethora of po-
tential insertional mutagens in its own architecture, in
the form of transposable elements (TEs) or ‘jumping
genes’. While sequences originating from TEs account
for a staggering 45% of the entire human genome, only a
relatively small set of 80–100 transposable elements are
still complete and capable of transposition [3].
The impact of TE mobilization on human cancer has
only recently become measurable, thanks largely to pro-
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article, unless otherwise stated.technologies. Evolution has endowed cells with a com-
plex arsenal of counter-measures to keep potentially
harmful mobilization of TEs in check. One such strat-
egy is based on the action of specialized ribonucleopro-
tein (RNP) complexes, at the core of which lie members of
the PIWI clade of Argonaute proteins and the small, non-
coding piRNAs associated with them. While research in
recent years has succeeded in unraveling several details of
PIWI-interacting RNAs (piRNAs) biogenesis and function
in transposon silencing, uncertainties remain on other as-
pects of their fascinating biology, such as the scope of
their function in post-transcriptional regulation of gene
expression and their suggested role in human cancer.
This article reviews the intersected fields of piRNA and
transposon biology and discusses some of the still rather
incomplete evidence in favor of a role of the PIWI/piRNA
axis in human cancer.
Retrotransposons and genome instability
Transposable elements in the human genome
The existence of transposable elements was first discov-
ered in maize by Barbara McClintock in the 1940s and
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to appreciate the universality of the phenomenon across
living forms. Transposable elements of the human genome
can be classified according to their mode of replication as
1) retrotransposons, which are transcribed into an RNA
intermediate, and 2) DNA transposons, which do not need
transcription to be mobilized (reviewed in [4]).
Much like retroviruses, retrotransposon transcripts
need to be retrotranscribed into cDNA by a reverse
transcriptase, which is itself encoded by the retrotrans-
poson. In turn, retrotransposons are classified as 1) LTR
retrotransposons, legacy of ancient germline retroviral
infections and believed to be inactive in humans, 2) long
interspersed elements 1 and 2 (LINE-1 and LINE-2 or
L1 and L2), and 3) short interspersed elements (SINEs),
in turn belonging to the SINE-Alu and SVA classes.
While LINEs encode a reverse transcriptase (and are
therefore called ‘autonomous’), SINEs do not and de-
pend on the two proteins encoded by LINEs for their
own replication and integration. DNA transposons con-
stitute less than 2% of the human genome and depend
on various transposases for their mobilization and inser-
tion in their new position in the genome. Only a subset
of about 80 to 100 copies of LINE-1 are competent for
transposition in humans [5]. These L1s are therefore re-
sponsible for the entire retrotransposition activity still
present in the human genome, as the two proteins they
encode are hijacked by SINEs for their own cycle of ret-
rotranscription and genomic integration.
LINE-1 elements are about 6 kb long and encode two
proteins, called ORF1p and ORF2p. The 5′UTR carries
an internal promoter, as well as an antisense promoter,
whose function is not clear. With their astounding abun-
dance of about 400,000 largely defective copies, they
make up close to 17% of the human genome [3]. ORF1p
is an RNA-binding protein required for the formation of
the retrotransposon particle, while ORF2p carries the
two crucial enzymatic activities required for retrotran-
sposition: reverse transcription and endonuclease.
The LINE-1 transposition cycle begins with transcrip-
tion, driven by the internal promoter, followed by export
of the bicistronic mRNA to the cytoplasm, where trans-
lation of ORF1p and ORF2p takes place. The ORF1p
protein shows a strong preference for binding the tran-
script molecule that encoded for itself, a phenomenon
called cis-preference [6]. ORF1p’s biochemical function
is not entirely deciphered, but the co-crystal structure of
ORF1p and LINE-1 RNA shows that trimers of the pro-
tein form a flexible nucleic acid chaperone, around
which a single strand of RNA is wrapped, a spatial ar-
rangement likely to contribute to the stability and nu-
clear import of the complex [7]. An L1 cytoplasmic RNP
particle is thus formed, which also includes ORF2p, the
second protein encoded by L1 elements.While the full spectrum of ORF1p binding targets
within the transcriptome has not been systematically
studied, LINE-1 transcripts are not the only RNA bound
by ORF1p: cellular transcripts present in the cytoplasm
can be loaded in the complex, albeit at a much lower
frequency, leading to the genomic insertion of their cor-
responding cDNAs in the form of pseudogenes [6]. Fur-
thermore, transcripts from non-autonomous SINE (Alu,
SVA) are frequently loaded into these RNP complexes,
leading to their insertion into new genomic locations. Fi-
nally, the L1 RNP enters the nucleus, where the enzym-
atic activities of ORF2p lead to genomic integration.
ORF2p is a large protein, with reverse transcriptase
and endonuclease activities. The widely accepted bio-
chemical model of L1 integration, called target-primed
reverse transcription (TPRT), postulates that, following a
nick in one DNA strand corresponding to the recogni-
tion sequence (5′-TTAAA-3′), the reverse transcriptase
activity of ORF2p extends the DNA 3′ end using L1
RNA as its template [8]. The sequence specificity of the
endonuclease is not the sole determinant of the choice
of integration site. Recent in vitro studies show that the
extent of base pairing within the DNA-RNA hybrid
formed by the ten bases at the 3′ end of LINE-1 RNA
with the nicked DNA affects the efficiency of L1 ORF2p-
mediated DNA extension [9]. Such mechanistic studies
are beginning to shed light on the complexity of the
events leading to integration site choice, which results in
a wide range of potential target sites [10].
The biochemical mechanism of L1 integration subse-
quent to retrotranscription initiation, including synthesis of
the second strand of cDNA and ligation of the 3′ ends of
the newly retrotranscribed DNA into genomic DNA, is un-
known. Such events result in some signature features sur-
rounding LINE-1 integrated in the genome, such as target
site duplication (TSD), stretches of identical 5–30 nucleo-
tides at the two ends of the integrated L1 element [11]. The
predominant occurrence of 5′ end deletion in integrated
LINE-1 elements is most likely a consequence of the 3′ to
5′ direction of reverse transcription and makes the over-
whelming majority of them incapable of retrotransposition.
L1 retrotransposition: when and where
Detection of abundant L1 transcripts and proteins
brought forth the concept that transposition takes place
actively in germ cells [12,13]. Subsequent studies in
transgenic mice, while confirming the presence of L1
transcripts in the germline, failed to reveal frequent gen-
omic insertion in this cell population; L1 elements ap-
pear instead to integrate in the genome in the early
phases of embryonic development, mostly in somatic tis-
sues, suggesting the presence of post-transcriptional
mechanisms specifically devoted to the preservation of
genomic integrity from TE insertion in gametes [14].
Moyano and Stefani Journal of Hematology & Oncology  (2015) 8:38 Page 3 of 10Despite the presence of multi-layered mechanisms of
control in the germline (see below), transposons have
obviously managed to trick these mechanisms at various
times during evolution, becoming a major driving force
in the shaping of genomes, from their prodigious expan-
sion earlier in mammalian evolution to phylogenetically
recent differences among primates [15-17]. On the other
hand, the presence of L1 transcripts and non-heritable
retrotransposition events in somatic cells indicates that
TEs contribute to the establishment of mosaicism within
an individual [14]. There is abundant evidence of som-
atic retrotransposition in somatic cell types such as tes-
ticular endothelium and Leydig cells, myocardium, and
various types of primary human cells in culture [18-21].
Somatic retrotransposition in the brain has been exten-
sively documented, in species ranging from Drosophila
to human [22] (reviewed in [23]).
In all, the mounting evidence of retrotransposition in
somatic tissue, in particular in the brain, challenges the
concept that all cells in an individual’s soma have identi-
cal genomes (barring the genomic rearrangements in
lymphocytes), and supports a scenario where each indi-
vidual’s soma is a mosaic of somewhat genomically dif-
ferent cell populations. In this perspective, mobilization
of TEs can be seen as beneficial, providing a molecular
mechanism contributing to the astounding variety of
neuron types and connectivity, for instance [23]. On the
other hand, the presence of an active insertional muta-
gen within the genome can also be a powerful source of
instability, leading to a variety of human diseases.
Mechanisms of retrotransposon-induced genome
instability
The mechanisms through which TE mobilization can
lead to potentially harmful mutations are manifold
[4,24]. TEs (mostly Alu elements) provide a vast reper-
toire of homologous sequences scattered throughout the
genome that can be involved in non-allelic homologous
recombination (NAHR), which leads to deletions and
duplications [25,26]. NAHR-induced mutations are esti-
mated to be vastly more frequent than all the other TE-
induced mutations in human cancers (reviewed in [27]).
In addition, integration of TEs in exons can cause dis-
ease by creating frameshifts, leading to premature stop
codons and nonsense-mediated decay, or by inducing
exon skipping. Furthermore, TE, in particular Alu, can
introduce additional splicing sites upon incorporation
into exons (‘exonization’), creating novel, potentially det-
rimental alternative splicing isoforms [28]. Less fre-
quently, insertions of TEs can also cause large deletions
of coding sequence. The relatively weak polyadenylation
sites of LINEs are sometimes not processed as such,
leading to read-through transcription of sequences be-
longing to a flanking gene, their incorporation in anactive element, and their transduction to a novel gen-
omic location [29].
Additionally, the presence of many polyadenylation
sites in the sense strand of LINE-1, while likely to reduce
mobilization of functional elements, contributes to
worsen the impact of their insertion, by imparting sites
of transcriptional pausing and decreasing the overall effi-
ciency of transcription of the host gene [30]. LINE-1 can
also disrupt gene expression at the transcriptional level by
inducing the antisense transcription of genes flanking its
integration site through antisense promoter activity
present in its 5′UTR. Additional mechanisms of alteration
of gene expression, which might cause human disease, in-
clude silencing of flanking genes by heterochromatization
of the transposable element as a result of the cell’s control
mechanisms and other less frequent molecular phenom-
ena (reviewed in [24]).
The range of human pathologies associated with docu-
mented insertion of retrotransposons is vast and
expanding. Hancks and Kazazian compiled a list of 96
instances of single-gene disease described in the litera-
ture, from hemophilia to diabetes to cancer [4,23,31,32].
Mobilization of transposons and cancer
As mutagens with very limited sequence requirements for
insertion, LINE and SINE are natural candidate pathogenic
factors in cancer, a disease caused by mutations. In
addition, exposure to some environmental factors that are
known to increase cancer risk also promotes TE transcrip-
tion and promoter demethylation, supporting the notion
that transposition might be a causal mechanism of neo-
plasm [33-35]. Aging, a major risk factor for cancer in
humans, is also accompanied by increased TE mobilization
in yeast and, more broadly, increased somatic mosaicism
in humans [36-38].
Direct evidence of transposon activation in human
cancer and transformed cell lines have been gathered
over the past 20 years. Components of TEs, both tran-
scripts and proteins, are elevated in cancer compared to
normal tissues [33,39-43]. Consistent with a higher level
of transposon expression, methylation of transposon
promoters is decreased in cancer [44-47] (reviewed in
[48]). Both phenomena correlate with worse prognosis
and higher levels of metastasis, substantiating a patho-
genic role for transposon mobilization [43-47] (reviewed
in [48]). These observed correlations grant plausibility to
a model in which prolonged exposure to adverse envir-
onmental factors in aging organisms leads to increased
retrotransposition, with, in turn, increased risk of abro-
gation of tumor suppressor activities by one of the sev-
eral mechanisms outlined above.
As it is often the case for cancer mutations, an outstand-
ing question in the field has been whether these trans-
poson activities are ‘driver’ phenomena or consequence of
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instability that are hallmarks of cancer. Disruption of
genes with a well-established tumor suppressor activity by
retrotransposon integration provides a strong correlative
evidence for a pathogenetic role for such mutations. A
first instance of such occurrence was detected in 1992 in a
survey by Southern blot of the APC tumor suppressor
gene in 150 colorectal cancer samples. The shift in size of
one fragment by several kilobases led to the realization
that a LINE-1 sequence was inserted in the gene [49].
Developments in high-throughput sequencing tech-
nologies are beginning to allow a full-genome outlook
on the impact of TEs on carcinogenesis that was not
available just a few years ago. In a recent such study, a
survey of 43 full-genome paired-end sequencing data-
bases from five different cancer types revealed 194 in-
stances of novel, cancer-specific somatic insertions [50].
The pool of 64 loci that were affected by these insertions
included genes associated with tumor suppressor and cell
adhesion functions, with an overall enrichment of fre-
quently mutated genes, a feature associated with a driver
role in tumorigenesis [51]. The expression levels of the
genes targeted by transposition were decreased, consistent
with a functional role of transposon insertion [50].
In disagreement with the conclusions of this report,
the analysis of a large dataset of 290 cancer genomes,
while identifying a large number (2,850) of new somatic
transposition events occurring in cancer, failed to iden-
tify insertions with obvious pathogenic implications, such
as disruption of tumor suppressor genes, nor did it detect
changes in gene expression of the genes targeted by TE in-
tegration [52]. Using a method called retrotransposon cap-
ture sequencing (RC-seq), 19 hepatocellular carcinoma
(HPCC) genomes were analyzed for novel germline and
somatic transposition [53]. Two likely L1-mediated tumori-
genic mechanisms were unveiled. In 20% of the analyzed
genomes, the expression of the tumor suppressor mutated
in colorectal cancer (MCC) was drastically reduced by
germline L1 insertions, resulting in activation of the onco-
genic Wnt/β-catenin pathway. Furthermore, somatic inser-
tion in an intronic transcriptional enhancer resulted in the
interruption of a self-repression loop, leading to increased
expression of the oncogene ST18 [53].
In summary, while the overwhelming majority of
retrotransposon activity in tumors is not likely to be dir-
ectly driving neoplastic transformation, active retrotran-
sposition is a generator of genomic variability, from
which occasionally mutations that impair tumor sup-
pressor genes can arise [52,53].
Guardians of genome integrity: PIWIs and piRNAs
PIWI and piRNA biogenesis and mechanism of action
Several layers of control stem mobilization and spread-
ing of transposons in normal cells. Different stages of aretrotransposon’s life cycle are targeted by such control
mechanisms: the exonuclease Trex1, which is also in-
volved in cell response to retroviral infection, degrades
single-stranded cDNA deriving from retrotransposons,
while the APOBEC3 cytidine deaminase family inhibits
retrotransposition through a variety of molecular pro-
cesses [54] (reviewed in [24]). In addition to these mech-
anisms, studies during the last decade uncovered how
the cell leverages a complex level of RNA-based control
strategies to inhibit mobile elements at the early stages
of transcription as well as post-transcriptionally.
The functional architecture of the PIWI/piRNAs axis
shows similarities with other two well-characterized small,
non-coding RNA-based regulatory pathways, miRNAs and
siRNAs, chiefly among them the role of the RNA compo-
nent as a specificity factor through base pairing, in the con-
text of a RNP effector complex that includes members of
the AGO family of proteins. Biogenesis sets piRNAs apart
from the other families of small, non-coding RNAs: while
double-stranded or stem-loop precursors of siRNAs and
miRNAs are processed by the RNAse III Dicer, piRNAs are
mostly transcribed as large (up to 200 kb) single-stranded
precursors, which are processed independently from Dicer.
In addition, piRNAs form functional complexes exclusively
with members of the PIWI clade of Argonaute proteins.
The piRNAs of Drosophila and mice can be grouped
in three classes according to their origin: 1) repeat-
associated piRNAs derived from intergenic loci, called
piRNA clusters, that are enriched in transposon frag-
ments in Drosophila, zebrafish, and in a subset of piRNA
clusters in mice; 2) mRNA-derived piRNAs derived from
the 3′UTR of mRNAs; and 3) long, non-coding RNA-
derived piRNAs [55]. The biogenesis and functions of
repeat-associated piRNAs are much better understood
than the other two classes (reviewed in [55,56]).
In the simplest scenario, Drosophila gonad somatic cells,
the primary transcript is first cleaved, probably by the
riboendonuclease Zucchini. The 3′ fragment is incorpo-
rated in PIWI proteins and trimmed to a final length of
~25 nt by a 3′ to 5′ exonuclease. The 5′ end residue of
the piRNA incorporated in PIWI shows a strong bias for
uridine residues, while the 2′ hydroxy group at the 3′ end
is methylated by the enzyme Hen1. The final length of
piRNAs is likely dictated by the extent of protection from
exonuclease trimming, as each PIWI protein binds a sub-
population of piRNAs with slightly different modal sizes
(25.7, 24.7, and 24.1 nt for Piwi, Aubergine (Aub), and
AGO3, respectively) [57]. The PIWI/piRNA complex en-
ters the nucleus, is targeted to actively transcribed nascent
transposon by recognition of sequences complementary to
its piRNA component, and inhibits further transcription
by recruiting histone methyltransferases, which will lead
to the establishment of transcriptionally silent heterochro-
matin [58].
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ition of transposon mobilization is amplified through the
‘ping-pong’ mechanism (Figure 1). Primary piRNAs, anti-
sense to transposons, are incorporated in the Aub PIWI
protein and target complementary transposon RNA se-
quences in the cytoplasm. Aub cleaves transposon RNA
between residues complementary to the 10th and 11th
piRNA residues. The resulting 3′ fragment of the trans-
poson RNA is incorporated in AGO3, another PIWI pro-
tein, trimmed and modified with a 2′ O-methylation, thus
forming a secondary piRNA, which will therefore begin
with ten residues complementary to the first ten residues
of the primary piRNA, with an adenosine as its tenth
residue complementary to the first uridine residue of the
primary piRNA. When the AGO3-secondary piRNA com-
plex targets antisense strand piRNA cluster transcripts, it
will produce new piRNAs identical to primary piRNAs,
which will be incorporated in Aubergine complexes, per-
petuating the cycle. This mechanism degrades transposon
RNA while amplifying the pool of piRNA/PIWI complexes
that can inhibit its expression at the transcriptional and
post-transcriptional levels (reviewed in [55]).
In mammals, piRNA/PIWI mechanisms display even
more variety. The earliest piRNA population, bound to
MILI and MIWI2, inhibits transcription of transposonsFigure 1 Biogenesis of piRNAs: piRNAs are generated from primary and se
general architecture of these pathways is largely conserved across animals.
endonuclease, most likely Zucchini. Cleaved precursors are incorporated in
at the 5′ end. Subsequently, an exonuclease activity trims the 3′ end to a f
3′ end is then methylated by the Hen enzyme. Aub-bound piRNAs can be am
cleavage of a complementary sense transcript by Aub, its trimming, modificat
inhibition of expression of piRNA targets by methylation at the DNA level and
see text for details).independently of cleavage activity and fades away soon
after birth [59]. A mechanism of amplification closely re-
sembling Drosophila ping-pong is carried out in prenatal
murine testis by the PIWI protein MILI and provides
secondary piRNAs bound by MIWI2 [60]. Post-natally,
two populations of piRNAs are found in pre-pachytene
and pachytene spermatocytes, respectively. The former
derives from 3′UTR regions of mRNAs, while the latter,
an extremely abundant population of short RNAs, stems
from lncRNAs. While genetic ablation experiments show
that both these piRNA classes are required for correct
spermatogenesis, their molecular function remains a
mystery. These very abundant piRNAs do not bear any
complementarity to transposable elements, suggesting
that they might have a different molecular target. A re-
cent report suggests that pachytene piRNAs and MIWI
target up to 40% of mRNAs in elongating spermatids,
leading to their deadenylation and degradation during
spermiogenesis [61].
Further evidence of the wide scope of the PIWI/
piRNA-mediated regulation of gene expression comes
from studies in simpler organisms. In Caenorhabditis
elegans, piRNA-like molecules, called 21U RNAs, are at
the center of a complex sequence-scanning system that
enables cells to detect non-self sequences such as mobilecondary pathways. While most exhaustively explored in Drosophila, the
In the primary pathway, antisense primary piRNAs are cleaved by an
Aubergine (AUB) or Piwi, with a strong preference for uridine residues
inal length likely to be dictated by protection by the Piwi protein. The
plified in the secondary pathway (ping-pong cycle), which involves the
ion, and incorporation in a complex with AGO3. The final outcome is the
by a variety of post-transcriptional mechanisms (not shown in the figure,
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their expression. This system relies on the production of
a large population of secondary siRNAs: upon recogni-
tion of a non-self mRNA by 21U RNAs, in a complex
with the PIWI protein PRG-1, the so-called 22G RNAs
are produced by an RNA-dependent RNA polymerase,
using the foreign RNA as template [61-64]. These sec-
ondary siRNAs target an effector Argonaute protein,
called WAGO-9, to complementary sequences (probably
nascent transcripts) in the nucleus, where heterochro-
matin proteins, DNA methylases, and other factors are
recruited to the site of transcription through interactions
with WAGO-9, contributing to silencing of the non-self
sequences. An opposing scanning system exists, which
guarantees the expression of ‘self ’ mRNAs. The se-
quence diversity of 21U RNAs is such that they could
conceivably target virtually the entire transcriptome,
similarly to mammalian ‘pachytene’ piRNAs: neutralizing
their inhibitory effect, yet another group of Argonaute
proteins (CSR-1, ALG-3, and ALG-4) forming complex
with a separate group of 22G and 26G RNAs promote
the proper expression of the genes required for germline
development and maintenance [65]. Amazingly, such
positive regulators of small RNA/Argonaute complexes
are packed in the sperm and transmitted to the zygote,
thus providing a vehicle for trans-generational transmis-
sion of epigenetic information [65] (reviewed in [66]).
Ciliated protozoa also show evidence of genome-
scanning mechanisms based on small RNAs that share
piRNA features. These scanning RNAs (scnRNAs) regu-
late programmed DNA elimination, the process by
which extensive tracts of DNA are removed from the
genome of the haploid micronuclei when they conjugate
to form ‘somatic’ macronuclei. In Tetrahymena and
Paramecium, scRNAs mark the DNA sequences that are
designated for elimination, while in Oxytricha trifallax,
piRNAs mark genomic sequences to be retained [67,68].
In addition to chromatin silencing, piRNAs control
transposon and mRNA expression in the cytoplasm
through degradation and possibly through translational
inhibition and intracellular localization (reviewed in
[69]). Close to one third of human mRNAs carry
transposon-derived sequences in their 3′UTR, making
them potential targets for PIWI/piRNA complexes [70].
During maternal nanos mRNA elimination in Drosophila
early development, piRNAs complementary to regions of
the 3′UTR and components of the piRNA pathway are
required for its deadenylation and degradation [71]. The
ability of transposon-derived sequences to induce in-
stability to reporters has also been shown in mammalian
systems [72]. These evidence of the ability of the piRNA
surveillance system to degrade mRNAs and the perva-
sive diffusion of transposon sequences in the human
genome should be taken into account when consideringthe possible role of ectopically expressed PIWI proteins
and piRNAs in human cancer.
PIWI, piRNAs, and cancer
PIWI was originally discovered as a factor required for
the maintenance of germline stem cells [73]. Members
of the PIWI clade Argonaute are expressed in several
stem cell populations across organisms and tissues, most
robustly in the male germline in adult mammals
(reviewed in [74]). Additionally, PIWIs are expressed in
a large number of human cancers, of both germline and
somatic origin, such as seminomas, multiple myeloma,
and prostate, hepatocellular, breast, gastrointestinal,
ovarian, and endometrial cancer, among others, as well
as murine breast tumors, rhabdomyosarcoma, and me-
dulloblastoma [75-78].
As it is often the case, the question arises of whether
such findings point to an active role of PIWI in carcino-
genesis, as opposed to representing a mere byproduct of
dysregulated gene expression in cancer. Even though the
field suffers from a dearth of functional studies, fairly
solid correlation between expression of PIWI in cancer
and a record of poorer clinical outcome suggest an im-
pact on the biology of tumors. The expression of PIWI
proteins in gastric, colorectal, breast, and cervical cancer,
soft tissue sarcoma, adenocarcinoma of the pancreas, he-
patocellular carcinoma, glioma, and esophageal squa-
mous cell carcinoma correlates with a significant worse
prognosis [78-86] (reviewed in [87]).
The mechanisms through which ectopic expression of
PIWI affects the clinical outcome of cancers are largely
unexplored. In one case, expression of PIWIL2 in three
different cell types has been shown to profoundly affect
the transcriptome, leading to a marked increase of the
antiapoptotic gene Bcl-XL, as well as Stat3 and cyclin
D1. These changes in gene expression were accompan-
ied by reduced apoptosis, increased proliferation, and
transformation [78]. In contrast, the simultaneous ec-
topic expression of piRNAs with PIWI proteins has been
only documented in a handful of cases. In gastric cancer
and multiple myeloma cell lines, piRNA-823 levels affect
tumor aggressiveness, albeit, strangely, in opposite direc-
tions: in gastric cancer cells, piRNA-823 has an overall
tumor suppressor activity, while in multiple myeloma, it
promotes cancer development, suggesting perhaps func-
tional interactions with cell-specific factors [77,88].
Overall, the current picture of the role of the piRNA/
PIWI axis in human cancer is probably incomplete, mir-
roring the gaps in our grasp of its physiological role. If
the sole function of piRNAs was to inhibit the
mobilization of transposons, one would expect the ec-
topic expression of PIWI proteins in cancer to exert an
overall antagonistic effect to tumor development and
progression. This is not the case in the overwhelming
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perturbed in tumor cells: ectopic expression of PIWI ac-
tually imparts a more aggressive cancer behavior, and its
inhibition reverses such phenotype. One can envision a
scenario in which widespread demethylation leads to
both activation of transposons and expression of PIWI
proteins, or, alternatively, one in which the expression of
PIWI proteins is somehow reactive to the activation of
transposons through some unknown mechanism [89,90].
Either way, once expressed in the wrong cell types and
at the wrong developmental time, PIWI proteins are
likely to be engaged not exclusively in the repression of
transposon mobilization but also in repressive interac-
tions with RNAs they are not exposed to in germline
cells. Post-transcriptional inhibition of gene expression
by piRNAs through degradation or translational inhib-
ition could be responsible for the documented tumor-
promoting effects. In such a scenario, PIWI/piRNA pro-
cancer action would be reminiscent of the oncogenic
role of some miRNA-Ago complexes such as miR-155,
miR-21, or the miR-17-92 cluster [91-93]. The two
modes of action of PIWI/piRNAs, transposon inhibition
and post-transcriptional silencing of mRNAs, could still
mechanistically be two sides of the same coin, as many
mRNAs include extensive transposon-derived sequences
[70]. Additionally, it cannot be ruled out at present that
PIWI’s and possibly piRNAs’ role in cancer could be
completely decoupled from control of transposon
mobilization. As mentioned in the previous section,
PIWI, piRNAs, and the Argonaute proteins WAGO-9
and CSR-1 and their cognate 22G and 26G RNAs are
intertwined in a complex system that allows C. elegans
to differentiate between ‘self ’ from ‘non-self ’ RNA [65].
Are mammalian PIWIs and piRNAs also part of an as
yet undiscovered mammalian mechanism of vigilance
on the proper expression of ‘self ’ RNA, and is the de-
rangement of such system somewhat at play in cancer?
While vertebrates seem to lack 22G and 26G RNAs,
the incredibly high number and sequence diversity of
the ‘pachytene’ piRNAs associated to MIWI in mouse
provides a repertoire of small, non-coding RNA that
could, in principle, target the entire human transcrip-
tome through imperfect complementarity. It is tempt-
ing to speculate that the improper activation of such a
far-reaching apparatus normally devoted to the moni-
toring of proper gene expression in the germline may
have profound consequence for the biological behavior
of cancer.
What are the broader implications of PIWI and pos-
sibly piRNA expression in cancer cells? One suggestion
comes from a Drosophila model of brain cancer: the ab-
lation of the l(3)mbt gene, a member of the polycomb
group (PcG) of proteins, leads to the development of
brain tumors. Expression profiling revealed a ‘l(3)mbttumor signature’ of 102 upregulated genes, which in-
cluded piwi. Mutation of piwi was sufficient to suppress
l(3)mbt malignant growth, providing strong in vivo evi-
dence for its requirement for l(3)mbt tumor formation.
Remarkably, 26 out of 102 upregulated genes that con-
stitute the ‘l(3)mbt tumor signature’ are required for
germline development and maintenance. They include
vasa and aubergine, which are, like piwi, involved in the
piRNA pathway and were able to suppress the l(3)mbt
penotype [94]. An extraordinary coordinated ectopic ex-
pression of genes normally restricted to the germline has
also been observed in the C. elegans ‘soma to germline’
switch upon suppression of lin-35, an ortholog of RB
(retinoblastoma protein), which interacts functionally
and associates physically with l(3)mbt, as well as in long-
lived mutants of the insulin-like pathway [95,96]. Add-
itionally, long-running efforts in the medical community
to identify cancer-specific antigen for immunotherapy
have resulted in the identification of tens of genes whose
expression is exquisitely restricted to the male germline
but becomes ectopically activated in a coordinated
fashion in a variety of tumors [97]. The products of
these genes have been therefore called cancer/testis
(CT) antigens. The common thread of the ectopic, co-
ordinated expression of genes that are normally
germline-restricted in somatic cancer has led to the
speculation that, by conferring biological features typ-
ical of the germline, CT antigens might contribute to
the biology of cancer cells [97]. Cellular behaviors ob-
served in gametogenesis, such as immortalization,
implantation, and migration, may be seen as corre-
sponding to, respectively, transformation, invasion, and
metastasis in the context of cancer, while other phe-
nomena such as global hypomethylation, active angio-
genesis, and immune evasion are common to both cell
types [97]. In this scenario, PIWI proteins ectopically
expressed in tumors could contribute to confer features of
actively replicating germline stem cells to cancer stem cells.
Conclusions and perspectives
Seventeen years after the discovery of PIWI and eight
after that of piRNAs, the extent of their role in cancer,
suggested by ectopic expression and correlation to clin-
ical outcome, is still far from being clearly understood.
Addressing the following questions would go a long way
in substantially advancing this area of cancer biology:
1) Are piRNAs ectopically expressed in cancer? While
PIWI protein expression in cancer is quite
extensively documented, piRNAs have been detected
in a handful of cases. These include a Drosophila
model of brain tumor and human multiple myeloma
and gastric cancer samples [77,88,94]. The
biogenesis of piRNAs is a complex process that
Moyano and Stefani Journal of Hematology & Oncology  (2015) 8:38 Page 8 of 10needs numerous factors, the expression of many of
which has not been studied in most cancers where
PIWI is expressed. In the absence of piRNAs, PIWI
could perhaps bind other RNAs or engage in
functional interactions of a radically different kind.
2) Which genes are regulated by piRNAs and PIWI
proteins in cancer? The understanding of the
biological functions of any trans-regulator of gene
expression is greatly advanced by the identification
of its functional targets. The field of RNA-binding
protein and miRNA-Argonaute biology has benefited
from addressing this question through experimental
approaches such as high-throughput sequencing of
RNA isolated by crosslinking immunoprecipitation
(HITS-CLIP) or crosslinking, ligation, and sequencing
of hybrids (CLASH) [98,99]. HITS-CLIP for Mili and
Miwi in mouse testis reached the unexpected
conclusion that Miwi binds mRNAs in the absence of
a piRNA guide [100]. Can this finding be confirmed in
cancer? Does the identity of genes regulated by
ectopically expressed PIWI proteins point to a specific
cellular process?
3) Is the ectopic expression of PIWI proteins and
piRNAs driving cancer development and
progression? More extensive studies in vertebrate
animal models are necessary to address this
fundamental question. In Drosophila, the
requirement of piwi for brain tumor formation has
been elegantly demonstrated in l(3)mbt, piwi double
mutants. Establishing similar models of ectopic
expression of PIWI and piRNAs in mammalian
model organisms will provide necessary information
on their capability to exert a causative role in the
initiation and progression of neoplasms.
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